Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
18.35
-0.24 (-1.29%)
Nov 17, 2025, 2:14 PM CST
SHA:600161 Revenue
Beijing Tiantan Biological Products had revenue of 1.35B CNY in the quarter ending September 30, 2025, with 9.96% growth. This brings the company's revenue in the last twelve months to 6.42B, up 22.78% year-over-year. In the year 2024, Beijing Tiantan Biological Products had annual revenue of 6.03B with 16.44% growth.
Revenue (ttm)
6.42B
Revenue Growth
+22.78%
P/S Ratio
5.72
Revenue / Employee
1.21M
Employees
5,298
Market Cap
36.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.03B | 851.42M | 16.44% |
| Dec 31, 2023 | 5.18B | 919.14M | 21.57% |
| Dec 31, 2022 | 4.26B | 149.15M | 3.63% |
| Dec 31, 2021 | 4.11B | 666.56M | 19.35% |
| Dec 31, 2020 | 3.45B | 163.74M | 4.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.88B |
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |